Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia

Catharina Müller-Thomas; Martina Rudelius; Ina Christine Rondak; Torsten Haferlach; Julie Schanz; Christina Huberle; Burkhard Schmidt; Rainer Blaser; Marcus Kremer; Christian Peschel; Ulrich Germing; Uwe Platzbecker; Katharina Götze

doi:10.3324/haematol.2014.104760

Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia

Catharina Müller-Thomas
, Martina Rudelius
, Ina Christine Rondak
, Torsten Haferlach
, Julie Schanz
, Christina Huberle
, Burkhard Schmidt
, Rainer Blaser
, Marcus Kremer
, Christian Peschel
, Ulrich Germing
, Uwe Platzbecker
, Katharina Götze

Technical University of Munich
University of Würzburg
Munich Leukemia Laboratory (MLL)
Georg-August-Universität Göttingen
Hematology and Oncology Pasing
Institute of Pathology
German Cancer Research Center
Heinrich-Heine-University
Technischen Universität Dresden

Research output: Contribution to journal › Letter › peer-review

57 Scopus citations

Original language	English
Pages (from-to)	e179-e181
Journal	Haematologica
Volume	99
Issue number	10
DOIs	https://doi.org/10.3324/haematol.2014.104760
State	Published - 1 Oct 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Azacitidine
MDS
TP53 mutations
p53 expression

Access to Document

10.3324/haematol.2014.104760

Cite this

Müller-Thomas, C., Rudelius, M., Rondak, I. C., Haferlach, T., Schanz, J., Huberle, C., Schmidt, B., Blaser, R., Kremer, M., Peschel, C., Germing, U., Platzbecker, U., & Götze, K. (2014). Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia. Haematologica, 99(10), e179-e181. https://doi.org/10.3324/haematol.2014.104760

@article{ba89f19c77a74b41b0d86a7c9bacc404,

title = "Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia",

keywords = "Azacitidine, MDS, TP53 mutations, p53 expression",

author = "Catharina M{\"u}ller-Thomas and Martina Rudelius and Rondak, \{Ina Christine\} and Torsten Haferlach and Julie Schanz and Christina Huberle and Burkhard Schmidt and Rainer Blaser and Marcus Kremer and Christian Peschel and Ulrich Germing and Uwe Platzbecker and Katharina G{\"o}tze",

year = "2014",

month = oct,

day = "1",

doi = "10.3324/haematol.2014.104760",

language = "English",

volume = "99",

pages = "e179--e181",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "10",

}

Müller-Thomas, C, Rudelius, M, Rondak, IC, Haferlach, T, Schanz, J, Huberle, C, Schmidt, B, Blaser, R, Kremer, M, Peschel, C, Germing, U, Platzbecker, U & Götze, K 2014, 'Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia', Haematologica, vol. 99, no. 10, pp. e179-e181. https://doi.org/10.3324/haematol.2014.104760

TY - JOUR

T1 - Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia

AU - Müller-Thomas, Catharina

AU - Rudelius, Martina

AU - Rondak, Ina Christine

AU - Haferlach, Torsten

AU - Schanz, Julie

AU - Huberle, Christina

AU - Schmidt, Burkhard

AU - Blaser, Rainer

AU - Kremer, Marcus

AU - Peschel, Christian

AU - Germing, Ulrich

AU - Platzbecker, Uwe

AU - Götze, Katharina

PY - 2014/10/1

Y1 - 2014/10/1

KW - Azacitidine

KW - MDS

KW - TP53 mutations

KW - p53 expression

UR - https://www.scopus.com/pages/publications/84907504886

U2 - 10.3324/haematol.2014.104760

DO - 10.3324/haematol.2014.104760

M3 - Letter

C2 - 24972774

AN - SCOPUS:84907504886

SN - 0390-6078

VL - 99

SP - e179-e181

JO - Haematologica

JF - Haematologica

IS - 10

ER -

Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia

UN SDGs

Keywords

Access to Document

Other files and links

Cite this